← Back to Search

ALRN-6924 for Small Cell Lung Cancer

Phase 1
Waitlist Available
Research Sponsored by Aileron Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histopathological confirmation of Stage IV NSCLC of adenocarcinoma histology. Cytological diagnosis of NSCLC is acceptable if sufficient tumor tissue is available for p53 mutation analysis. FDA approved liquid biopsies are also acceptable.
Presence of one or more p53 mutations.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 19 months
Awards & highlights

Study Summary

This trial is studying a drug to see if it can help prevent side effects from chemotherapy in patients with lung cancer.

Eligible Conditions
  • Small Cell Lung Cancer
  • Non-Small Cell Lung Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 19 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 19 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Phase 1b Part 1 SCLC
Phase 1b Part 2 NSCLC

Trial Design

3Treatment groups
Experimental Treatment
Group I: Part 2 NSCLC: Placebo+Carboplatin+PemetrexedExperimental Treatment3 Interventions
Group II: Part 2 NSCLC: ALRN-6924+Carboplatin+PemetrexedExperimental Treatment3 Interventions
Group III: Part 1 SCLC: ALRN-6924+TopotecanExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALRN-6924
2018
Completed Phase 2
~230
Placebo
1995
Completed Phase 3
~2670
Carboplatin
2014
Completed Phase 3
~6670
Pemetrexed
2014
Completed Phase 3
~5250
Topotecan
2017
Completed Phase 3
~2400

Find a Location

Who is running the clinical trial?

Aileron Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
264 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Mar 2025